Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.47 |
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18611678 | 0.90 | MGLL (0.59) | MGLLMEN1KMT2AKAT6AGAA | |
| SCHEMBL12420768 | 0.89 | MEN1 (0.47) | MGLLMEN1KMT2ASIGMAR1GAA | |
| Hydrochloric Acid SCHEMBL2196700 | 0.88 | MEN1 (0.47) | MGLLMEN1KMT2ASIGMAR1GAA | |
| SCHEMBL12735911 | 0.85 | PARP15 (0.59) | MEN1KMT2ASIGMAR1RBP4ALDH1A1 | |
| SCHEMBL12735908 | 0.85 | PARP15 (0.59) | MEN1KMT2ASIGMAR1RBP4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1532819 | 0.84 | PARP15 (0.58) | MEN1KMT2ASIGMAR1RBP4ALDH1A1 | |
| SCHEMBL30170608 | 0.84 | MGLL (0.52) | MGLLMEN1KMT2AGAAHTT | |
| SCHEMBL13806533 | 0.84 | PARP15 (0.58) | MEN1KMT2ASIGMAR1RBP4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30170667 | 0.83 | MGLL (0.51) | MGLLMEN1KMT2AGAAHTT | |
| SCHEMBL15062224 | 0.82 | PARP15 (0.55) | MEN1KMT2ASIGMAR1RBP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | MGLL 263/4885MEN1 4707/4885KMT2A 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.